Commentary warns of unintended consequences from the use of inhibitor proton pump in reflux disease

Despite the very effective and beneficial for many patients, unintended consequences are characterized patients prescribed inhibitors proton pump inhibitors (PPI) for reflux disease. Doctors have been alerted to monitor these effects and to prescribe these drugs carefully, according to a new commentary in the November issue of 2009 published in Otolaryngology - Head and Neck Surgery. The authors disease gastroesophageal reflux disease (GERD) and laryngopharyngeal reflux (LPR) are diseases that have experienced a remarkable growth in the relevance of public health over the past 20 years. While it has always been known that more than 50 percent of adults in Western countries have occasional reflux symptoms, there are more than four times the number of medical patients for their symptoms.

Les IPP sont une classe de médicaments importants et en toute sécurité en général, que la libération de l'acide gastrique, qui empêchent une cause de licenciement de nombreux patients atteints de reflux expérience. PPIs are among the classes most commonly prescribed drugs for the disease of gastro-esophageal reflux and LPR. But the authors believe there is a growing number of studies demonstrating that acidity is not the only cause tissue damage in reflux disease, and PPIs are not effective in treating all cases of gastro-esophageal reflux and LPR.

In addition to the evidence that is not the only contribution to disease agents of acid reflux seeking authors of recent research on EPI noted that there are many unintended and undesirable consequences of this drug class. You can include an increased incidence of hip fractures, calcium absorption may be altered, but not proven possible vitamin B12 and iron absorption changes to changing associated gastric pH, increased the chances of acquisition of nosocomial Clostridium difficile associated diarrhea and a higher rate of contracting community acquired pneumonia.

The authors say that it is premature to make recommendations on global trends in prescribing of PPIs, they welcome the idea of increasing clinical awareness of this class of drugs and its possible unintended consequences. In addition, the evaluation and appropriate monitoring of patients taking PPIs important to determine the need and duration of drug use. The authors recommend other doctors to treat patients with reflux on the risks of treatment against the risks of treatment of the disease to examine and assess a target includes a holistic approach to food and changing habits life. These additional measures may be useful to reduce the costs of health care are associated with reflux disease, and encourages patients to continue to practice behaviors that improve their overall health.